Up­dat­ed: FDA ap­proves Al­ny­lam’s Amvut­tra in AT­TR-CM, kick­ing off com­pe­ti­tion with Pfiz­er, Bridge­Bio

The FDA on Thurs­day ap­proved Al­ny­lam’s Amvut­tra for a rare heart dis­ease, giv­ing the com­pa­ny an ex­pect­ed yet sig­nif­i­cant win.

Amvut­tra is now ap­proved to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER